FcRn
Assets acting on this target.
- Class
- FcRn blocker (IgG1 Fc fragment)
By indication
FcRn drugs compared
3 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Efgartigimod AlfaVyvgart | argenx, Zai Lab | antibody fragment | Approved | Approved in Generalized Myasthenia Gravis; Approved in Myasthenia Gravis |
| Efgartigimod alfa and hyaluronidase (Vyvgart Hytrulo)Vyvgart Hytrulo | argenx | antibody fragment | Approved | Approved in Chronic Inflammatory Demyelinating Polyneuropathy; Approved in Generalized Myasthenia Gravis |
| Imeroprubart | HanAll BioPharma, Immunovant, Inc., Roivant Sciences Ltd. | monoclonal antibody | Phase 3 | Phase 3 in Myasthenia Gravis; Phase 2 in Chronic Inflammatory Demyelinating Polyneuropathy; Phase 2 in Graves' Disease; Phase 2 in Rheumatoid Arthritis; Phase 2 in Sjögren's Disease |